Single-cell technologies that capture chromatin accessibility profiles such as single-cell Assay for Transposase-Accessible Chromatin using sequencing could help explore the influence of epigenomic variability on the heterogeneity of resistance to cancer drug such as TRAIL (Buenrostro et al, 2015; Litzenburger et al, 2017). This evidence concerns the gene TNFSF10 and cancer.